John M. Leonard

CIK: 0001563584

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)7 (50.0%)

Position reduction

Option Exercises (M)3 (21.4%)

Derivative conversions

Awards (A)4 (28.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

NTLA

Intellia Therapeutics, Inc.

DirectorOfficer

IQV

IQVIA HOLDINGS INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (14 total)

NTLA
Intellia Therapeutics, Inc.
Aug 21, 2026
Sale(S)
Direct
2.8K shares at avg. $13.00$36K
NTLA
Intellia Therapeutics, Inc.
Aug 20, 2026
Sale(S)
Direct
19.9K shares at avg. $12.60$251K
IQV
IQVIA HOLDINGS INC.
Apr 23, 2026
Award(A)
Direct
1.6K shares-
NTLA
Intellia Therapeutics, Inc.
Mar 1, 2026
Award(A)
Direct
156.4K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
34.1K shares at avg. $9.21$314K
NTLA
Intellia Therapeutics, Inc.
Dec 12, 2025
Exercise(M)
Direct
8.6K shares at avg. $6.83$58K
NTLA
Intellia Therapeutics, Inc.
Dec 11, 2025
Sale(S)
Direct
50K shares at avg. $9.49$474K
NTLA
Intellia Therapeutics, Inc.
Dec 11, 2025
Sale(S)
Direct
5.4K shares at avg. $9.59$51K
NTLA
Intellia Therapeutics, Inc.
Dec 11, 2025
Exercise(M)
Direct
50K shares at avg. $6.83$341K
NTLA
Intellia Therapeutics, Inc.
Dec 11, 2025
Sale(S)
Direct
32.8K shares at avg. $9.47$311K
IQV
IQVIA HOLDINGS INC.
Apr 24, 2025
Award(A)
Direct
1.6K shares-
NTLA
Intellia Therapeutics, Inc.
Mar 1, 2025
Award(A)
Direct
136K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 3, 2025
Sale(S)
Direct
26.8K shares at avg. $12.18$327K
NTLA
Intellia Therapeutics, Inc.
Jan 1, 2025
Exercise(M)
Direct
7.9K shares-

		Type	Shares	Price		Ownership
Aug 21, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	2,785	$13.00	$36,205	Direct
Aug 20, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	19,890	$12.60	$250,614	Direct
Apr 23, 2026	IQV IQVIA HOLDINGS INC.	Award(A)	1,571	-	$0	Direct
Mar 1, 2026	NTLA Intellia Therapeutics, Inc.	Award(A)	156,400	-	$0	Direct
Jan 5, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	34,146	$9.21	$314,485	Direct
Dec 12, 2025	NTLA Intellia Therapeutics, Inc.	Exercise(M)	8,557	$6.83	$58,444	Direct
Dec 11, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	49,959	$9.49	$474,111	Direct
Dec 11, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	5,355	$9.59	$51,354	Direct
Dec 11, 2025	NTLA Intellia Therapeutics, Inc.	Exercise(M)	49,959	$6.83	$341,220	Direct
Dec 11, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	32,832	$9.47	$310,919	Direct
Apr 24, 2025	IQV IQVIA HOLDINGS INC.	Award(A)	1,592	-	-	Direct
Mar 1, 2025	NTLA Intellia Therapeutics, Inc.	Award(A)	136,000	-	-	Direct
Jan 3, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	26,807	$12.18	$326,509	Direct
Jan 1, 2025	NTLA Intellia Therapeutics, Inc.	Exercise(M)	7,850	-	$0	Direct

1-14 of 14 transactions

About LEONARD JOHN M

LEONARD JOHN M (SEC CIK 0001563584) files insider reports with the SEC as President and CEO of Intellia Therapeutics, Inc. (NTLA) and Director of IQVIA HOLDINGS INC. (IQV).

Signal8 holds 9 ownership filings by LEONARD JOHN M, all Form 4s, filed between Jan 3, 2025 and Aug 24, 2026. Those filings report 14 transactions, from Jan 1, 2025 to Aug 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on LEONARD JOHN M's filings is in CAMBRIDGE, MA.

Recent filings by LEONARD JOHN M

Aug 21, 2026: Open-market sale of NTLA shares (Form 4, code S).
Aug 20, 2026: Open-market sale of NTLA shares (Form 4, code S).
Apr 23, 2026: Grant or award of IQV shares (Form 4, code A).
Mar 1, 2026: Grant or award of NTLA shares (Form 4, code A).
Jan 5, 2026: Open-market sale of NTLA shares (Form 4, code S).

Other insiders filing for Intellia Therapeutics, Inc. (NTLA)

Marantz Jing L., EVP, Chief Medical Officer
Dube Michael P, VP, Chief Accounting Officer
Dulac Edward J III, EVP, Chief Financial Officer
Verwiel Frank, Director
Keresty Georgia, Director
GOODMAN JESSE, Director

How to read Form 4 transaction codes